MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
2.090
0.000
0.00%
After Hours: 2.055 -0.035 -1.67% 16:57 05/12 EDT
OPEN
2.100
PREV CLOSE
2.090
HIGH
2.110
LOW
2.060
VOLUME
53.06K
TURNOVER
--
52 WEEK HIGH
2.710
52 WEEK LOW
1.260
MARKET CAP
58.26M
P/E (TTM)
-2.7352
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMMX last week (0505-0509)?
Weekly Report · 17h ago
Weekly Report: what happened at IMMX last week (0428-0502)?
Weekly Report · 05/05 12:08
Weekly Report: what happened at IMMX last week (0421-0425)?
Weekly Report · 04/28 12:21
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Chosen For Oral Presentation at ASCO 2025
Benzinga · 04/23 14:07
IMMIX BIOPHARMA’S NXC-201 NEXICART-2 CLINICAL TRIAL DATA SELECTED FOR ORAL PRESENTATION AT ASCO 2025
Reuters · 04/23 14:04
Weekly Report: what happened at IMMX last week (0414-0418)?
Weekly Report · 04/21 12:20
Weekly Report: what happened at IMMX last week (0407-0411)?
Weekly Report · 04/14 12:05
Weekly Report: what happened at IMMX last week (0331-0404)?
Weekly Report · 04/07 12:05
More
About IMMX
More
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Recently
Symbol
Price
%Change

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.